Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors

Drug Discovery Today

Volumn 14, Issue 5-6, 2009, Pages 291-297

  Akritopoulou Zanze, Irini ^a   Hajduk, Philip J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 2; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PYRAZOLE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 INHIBITOR;

CRYSTAL STRUCTURE; DRUG BINDING; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HYDROGEN BOND; PATENT; REVIEW; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INTELLECTUAL PROPERTY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SMALL MOLECULE LIBRARIES;

EID: 61649114657     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.12.002     Document Type: Review

References (20)

1. Cohen P. Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
2. Weinmann H., and Metternich R. Drug discovery process for kinase inhibitors. Chembiochem 6 (2005) 455-459
3. Liao J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50 (2007) 409-424
4. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
5. Davis A.M., et al. Components of successful lead generation. Curr. Top. Med. Chem. 5 (2005) 421-439
6. Prien O. Target-family-oriented focused libraries for kinases-conceptual design aspects and commercial availability. Chembiochem 6 (2005) 500-505
7. Bogoyevitch M.A., and Fairlie D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug. Discov. Today 12 (2007) 622-633
8. Zhang C., and Kim S.-H. The impact of protein kinase structures on drug discovery. Comput. Struct. Appr. Drug Discov. 349 (2008) 349-365
9. Albert D.H., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5 (2006) 995-1006
10. Luo Y., et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4 (2005) 977-986
11. Wang L., et al. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. J. Med. Chem. 50 (2007) 4162-4176
12. Abad-Zapatero C., and Metz J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 10 (2005) 464-469
13. Hajduk P.J. Fragment-based drug design: how big is too big?. J. Med. Chem. 49 (2006) 6972-6976
14. Sutherland J.J., et al. Chemical fragments as foundations for understanding target space and activity prediction. J. Med. Chem. 51 (2008) 2689-2700
15. Meyer B., and Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem. Int. Ed. Engl. 42 (2003) 864-890
16. Hajduk P.J., et al. NMR-based screening in drug discovery. Q Rev. Biophys. 32 (1999) 211-240
17. Gracias V., et al. Scaffold oriented synthesis. Part 2: design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 2691-2695
18. Akritopoulou-Zanze I., et al. Scaffold oriented synthesis. Part 1: design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 96-99
19. Huth J.R., et al. Utilization of NMR-derived fragment leads in drug design. Methods Enzymol. 394 (2005) 549-571
20. Hann M.M., and Oprea T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8 (2004) 255-263